Dylan Marchione PhD

Company: Servier Pharmaceuticals

Job title: IDH Heme Biomarker Lead

Seminars:

Clonal evolution underlying clinical responses and relapses in patients with IDH1-mutated AML treated with ivosidenib monotherapy or ivosidenib + azacitidine 4:15 pm

•  Single-cell DNA sequencing reveals differences in the clonal evolution that occurs in patients with IDH1 mutated AML who are treated with ivosidenib depending on disease setting (frontline vs. relapsed/refractory) and treatment regimen (monotherapy vs. combination). •  The combination of ivosidenib with azacitidine yields a high objective response rate and durable clearance of mutant IDH1.…Read more

day: Day 1 - PM - red